MRC1 and female reproductive organ cancer: MMR-deficient tumors were associated with a significantly higher ORR (60.9% vs. 28.9%, <i>p</i> = 0.011), although MMR status was not independently associated with survival in the final multivariate models.<h4>Conclusion</h4>The development of immune-related adverse events and low pretreatment neutrophil-to-lymphocyte ratio independently predicted improved therapeutic response and prolonged survival in gynecologic cancer patients treated with pembrolizumab.